Dr. Sophelia HS Chan is a Clinical Associate Professor in Pediatric Neurology at the University of Hong Kong, specializing in rare neurological diseases, particularly neuromuscular disorders. She completed her Pediatric Neurology training at the University of Hong Kong and further developed her expertise through international fellowship training program at the Dubowitz Neuromuscular Centre at Great Ormond Street Hospital in London. Dr. Chan leads several international clinical trials on spinal muscular atrophy and Duchenne muscular dystrophy and oversees the SMA treatment program for pediatric patients in Hong Kong. With over 70 publications, she is a recognized researcher in her field, having received internal and external research grants (including HMRF, GRF, ITF, TDG), and research fellowship award. Dr. Chan also serves as an executive board member of the Asian Oceanian Myology Centre, a member of the Committee of Inclusion, Equity, and Diversity of the World Muscle Society, and the President of the Hong Kong Society of Neuromuscular Diseases. She is also an editorial board member of the journal Neuromuscular Disorders -- the official journal of the World Muscle Society.

Rimas J. Orentas, PhD, is Senior Scientific Director, R&D Immunotherapy, in Miltenyi Biotec, Inc. He leads groups focused on CAR-T cells, NK-CARs, gd T-cell and HSC-engineering in Gaithersburg, Maryland, USA and Bergisch-Gladbach, Germany. Dr. Orentas also holds an adjunct professorship in the Johns Hopkins Bloomberg School of Public Health. He is co-founder of Caring Cross, a non-profit implementing low-cost approaches to engineered cell therapies. He has led teams that delivered 6 first-in-human CAR-T products. Previous positions include Professor of Pediatrics, University of Washington School of Medicine, Director of the Ben Towne Center for Childhood Cancer Research (Seattle Children’s Research Institute); Scientific Director of Lentigen, a Miltenyi Biotec Company; Associate Scientist, Pediatric Oncology Branch, NCI, NIH, and faculty positions at the Medical College of Wisconsin.

Olaf Rötzschke obtained his PhD in 1993 at the University of Tübingen, Germany, where he studied biochemistry. He started his career at the Max-Planck Institute of Biology in the group of Hans-Georg Rammensee, where he isolated the first natural T cell antigen and defined the binding motifs of MHC molecules. In 1993 he joined the group of Jack Strominger at Harvard University, carrying out studies on the immune-modulation and antigen-presentation. In 2000 he moved to the Max-Delbrück-Center in Berlin focusing on regulatory T cells (Treg) and MHC ligand-exchange. He joined SIgN as Principal Investigator in July 2008 and in 2018 became also Head of two SIgN Immunomonitoring Platforms (‘Mass Cytometry’ and ‘Multiplex Analysis of Proteins’). Since 2011 he is also Adjunct Professor at the Nanyang Technological University (NTU) and Adjunct Associate Professor at the National University of Singapore (NUS). In March 2023 he launched the T cell Monitoring and Vaccine Development platform (T-MoVac), an island-wide initiative to establish a pipeline for the generation of personalized T cell vaccines for the treatment of cancer.

Dr Michaela Seng is a Paediatric haematologist and oncologist in KK Women’s and Children’s Hospital who holds full specialist accreditation in both Australia and Singapore. She currently serves as the BMTCT Clinical Facility medical director and research lead in the KK Women's and Children's Blood and Cancer Centre. Her research interest is in the translation of innovative cell therapies for relapsed refractory cancers, motivated by the treatment failures and toxicities seen in her practice. In this regard, she runs several investigator-initiated cell therapy trials for adult and paediatric patients as the Principle Investigator.